Bruker price target lowered to $80 from $95 at Citi

Citi analyst Patrick Donnelly lowered the firm’s price target on Bruker to $80 from $95 and keeps a Buy rating on the shares. In Life Sciences, investor sentiment has shifted more negative in recent weeks and the bar has been lowered for Q2, with the ability to meet expectations and demonstrate some level of visibility likely to be rewarded, the analyst tells investors in a research note. The firm is more cautious on the bioprocessing names given recent industry data points.